Shares of Flamel Technologies SA (NASDAQ:FLML) have received a consensus recommendation of “Buy” from the seven analysts that are currently covering the stock. Two analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $18.63.
A number of equities research analysts recently weighed in on FLML shares. Zacks Investment Research raised Flamel Technologies SA from a “sell” rating to a “hold” rating in a report on Tuesday, July 12th. Leerink Swann reaffirmed an “outperform” rating and set a $16.00 price target on shares of Flamel Technologies SA in a report on Tuesday, September 27th. Finally, JMP Securities reissued an “outperform” rating and issued a $16.00 target price on shares of Flamel Technologies SA in a research note on Wednesday, September 28th.
In other news, Director Francis Fildes sold 15,000 shares of the firm’s stock in a transaction on Thursday, September 22nd. The stock was sold at an average price of $13.45, for a total value of $201,750.00. Following the transaction, the director now directly owns 15,000 shares in the company, valued at approximately $201,750. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Michael S. Anderson purchased 5,000 shares of Flamel Technologies SA stock in a transaction dated Monday, August 22nd. The stock was bought at an average price of $14.30 per share, for a total transaction of $71,500.00. The disclosure for this purchase can be found here. 4.45% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Janus Capital Management LLC raised its position in Flamel Technologies SA by 647.0% in the second quarter. Janus Capital Management LLC now owns 2,197,404 shares of the company’s stock valued at $25,599,000 after buying an additional 1,903,256 shares in the last quarter. Acadian Asset Management LLC raised its position in Flamel Technologies SA by 240.2% in the second quarter. Acadian Asset Management LLC now owns 1,617,223 shares of the company’s stock valued at $17,372,000 after buying an additional 1,141,783 shares in the last quarter. Falcon Point Capital LLC raised its position in Flamel Technologies SA by 1.1% in the second quarter. Falcon Point Capital LLC now owns 1,015,841 shares of the company’s stock valued at $10,910,000 after buying an additional 10,973 shares in the last quarter. Brown Capital Management LLC raised its position in Flamel Technologies SA by 36.5% in the second quarter. Brown Capital Management LLC now owns 790,206 shares of the company’s stock valued at $8,487,000 after buying an additional 211,392 shares in the last quarter. Finally, Emerald Acquisition Ltd. bought a new position in Flamel Technologies SA during the second quarter valued at about $6,530,000. Institutional investors and hedge funds own 70.33% of the company’s stock.
Flamel Technologies SA (NASDAQ:FLML) last released its quarterly earnings results on Monday, August 8th. The company reported ($0.02) earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.06 by $0.08. Flamel Technologies SA had a net margin of 12.11% and a return on equity of 25.19%. The business had revenue of $38.90 million for the quarter, compared to analyst estimates of $32.80 million. During the same period in the prior year, the business earned $0.34 earnings per share. The company’s revenue for the quarter was down 20.0% on a year-over-year basis.
About Flamel Technologies SA
Flamel Technologies SA is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its polymer based technology. The Company has a balanced business model consisting of an Unapproved Marketed Drugs (UMDs) business with over two approved products in the United States, Bloxiverz (neostigmine methylsulfate injection) and Vazculep (phenylephrine hydrochloride injection) that are marketed; a branded pediatric business, and a branded business, focusing on the development of products utilizing Flamel’s drug delivery platforms.
Receive News & Ratings for Flamel Technologies SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flamel Technologies SA and related companies with MarketBeat.com's FREE daily email newsletter.